Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer (PESUP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01587534|
Recruitment Status : Completed
First Posted : April 30, 2012
Last Update Posted : April 15, 2015
National Cancer Center, Korea
Pharmbio Korea Co., Ltd.
Information provided by (Responsible Party):
Sang Myung Woo, National Cancer Center, Korea
No Study Results Posted on ClinicalTrials.gov for this Study
|Recruitment Status :||Completed|
|Actual Primary Completion Date :||December 2014|
|Actual Study Completion Date :||December 2014|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Woo SM, Joo J, Kim SY, Park SJ, Han SS, Kim TH, Koh YH, Chung SH, Kim YH, Moon H, Hong EK, Lee WJ. Efficacy of pancreatic exocrine replacement therapy for patients with unresectable pancreatic cancer in a randomized trial. Pancreatology. 2016 Nov - Dec;16(6):1099-1105. doi: 10.1016/j.pan.2016.09.001. Epub 2016 Sep 4.